Quantcast

Latest cancer therapies Stories

2011-06-06 07:00:00

LOS ANGELES, June 6, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced an expanded clinical focus to include an autologous cell therapy product candidate, Contego(TM), for the treatment of Stage IV metastatic melanoma. Anthony J. Cataldo, Chairman and Chief Executive Officer of Genesis Biopharma, and members of the Company's Scientific and Medical Advisory Board (SMAB) met in Chicago where SMAB...

2011-05-23 08:00:00

LOS ANGELES, May 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB:GNBP), a biotechnology company developing targeted cancer therapies, today announced that former California Governor, Gray Davis, has joined the company as Chairman of its Corporate Advisory Board. Governor Davis is committed to the improvement of healthcare and advancement of medical technologies. During his tenure as governor, California became a leader in stem cell research as well as providing the highest levels...

2011-05-18 11:49:00

LOS ANGELES, May 18, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer therapies, announces the formation of a Scientific and Medical Advisory Board. "We are very fortunate to have some of the nation's leading oncologists and cancer researchers providing insight and expertise to Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "This new advisory board will play a critical role in guiding the...

2011-03-17 07:00:00

LOS ANGELES, March 17, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has appointed William H. Andrews Ph.D. to its Board of Directors. Dr. Andrews has three decades experience in biotechnology research and development, and is currently President and Chief Executive Officer of Sierra Sciences, LLC, a company he founded in 1999. "Dr. Andrews brings a wealth of scientific expertise...

2011-03-10 15:01:00

BOTHELL, WA and VANCOUVER, March 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its fourth quarter and year end 2010 financial results, reviewed updates to the Company's development programs and provided an outlook for 2011. "Over the course of the last twelve months we've delivered on our corporate objectives to initiate two Phase 3 clinical trials evaluating custirsen in castrate-resistant prostate cancer and a randomized Phase 2...

2011-03-07 07:00:00

LOS ANGELES, March 7, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced it has named Marvin S. Hausman M.D. as Chief Science Officer. Dr. Hausman has 30 years of drug development and clinical care experience at various pharmaceutical companies. "We are very fortunate to have Marvin Hausman join the team at Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer....

2011-02-14 10:16:00

THE WOODLANDS, Texas, Feb. 14, 2011 /PRNewswire/ -- Through the continuous and tremendous growth of its patient assistance support program, US Oncology, Inc., a division of McKesson Corp. and a leading integrated oncology company, is helping cancer patients access the high quality cancer care they need. By helping patients obtain financial assistance, thousands can now afford much needed treatment and cancer therapies. (Logo: http://photos.prnewswire.com/prnh/20100517/DA06089LOGO) "If...

2011-02-11 07:00:00

LOS ANGELES, Feb. 11, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced that Anthony J. Cataldo has been named President and Chief Executive Officer. Mr. Cataldo succeeds Robert Brooke, who now serves as a strategic advisor to Genesis Biopharma. In addition, the Company named Michael Handelman as Chief Financial Officer, Treasurer and Secretary, succeeding Richard McKilligan. Mr....

2011-02-03 09:00:00

THE WOODLANDS, Texas, Feb. 3, 2011 /PRNewswire/ -- US Oncology, Inc., a division of McKesson Corp. and a leading integrated oncology company, announced today that Robert Raju, MD, FACP has brought US Oncology Research to Kettering Medical Center in Dayton, Ohio. The new program, built from the ground up, expands the US Oncology Research Translational Oncology Program (TOP) which conducts trials for patients with advanced cancer. This center will also include first-in-man trials, which can...

2011-01-24 08:00:00

MANHATTAN BEACH, Calif., Jan. 24, 2011/PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the company's support of the FDA's newly drafted "Guidance for Industry Codevelopment of Two or More Unmarketed Investigational Drugs for Use in Combination." This guidance document, designed to encourage companies to collaborate and seek approval for successfully developed drug combinations, would support...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.